ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Enanta Pharmaceuticals, a specialist in small-molecule drugs for infectious diseases, has entered a pact with Novartis for development, manufacture, and commercialization of its lead candidate, EDP-239, which comes from its NS5A hepatitis C virus inhibitor program. Enanta will receive an up-front payment of $34 million and is eligible for up to $406 million in milestone payments. NS5A is a nonstructural viral protein that is essential to viral replication. The protein has emerged as an important target for antiviral drug development, Enanta says.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter